Biomeostasis

👋 Welcome to the Biomeostasis’ Universe! We're delighted to welcome you to our LinkedIn community! 🎉 🚀 At Biomeostasis, we are passionate about advancing preclinical research to new heights. Our dedicated team of scientists is committed to delivering cutting-edge solutions that empower researchers, accelerate discoveries, and transform the way we approach preclinical studies. 🌟 What Sets Us Apart? 🔹 Scientific expertise: We are made up of 100% highly skilled and trained PhD scientists, offering valuable insights and guidance to achieve your goals. 🔹 Tailored Solutions: We understand the unique challenges of each study. Our solutions are customized to fit the specific needs of our clients, fostering successful outcomes. 🔹 Quality: We are known to deliver accurate & high-added value data. 🔬 Explore Our Services In the dynamic world of preclinical testing, choosing the right partner is crucial. With our state-of-the-art facilities, and a passion for scientific excellence, we stand as your trusted ally in every research endeavor. We offer in vivo pharmacology services in the following therapeutic areas: • Metabolic diseases • Gastrointestinal disorders • Age-related diseases 👉 Stay Connected Thank you for being part of our community! We look forward to inspiring, informing and assisting you in your preclinical journey. See you soon! The Biomeostasis team 🌟 #CRO #Preclinical #Biotech #DrugDiscovery #Science

🌿 𝐋𝐞𝐭'𝐬 𝐓𝐚𝐥𝐤 𝐀𝐛𝐨𝐮𝐭 𝐂𝐨𝐧𝐬𝐭𝐢𝐩𝐚𝐭𝐢𝐨𝐧 🌿 Did you know that #constipation affects approximately 16% of the global population? It is a common #gastrointestinal disorder, with higher prevalence observed in women and older adults. At Biomeostasis, we are committed to shedding light on this widespread issue and exploring innovative solutions through our research efforts. Constipation involves altered gut motility, slowed colonic transit, and changes in the gut microbiome. Studies in mice have linked these factors to gene expression changes related to gut function and microbiome health. Risk factors for constipation include low fiber intake, physical inactivity, certain medications, and underlying medical conditions such as diabetes, thyroid disorders, and neurological disorders. Recognizing these factors is crucial for effective management and prevention. Treatment options for constipation range from dietary adjustments (such as increased fiber and water intake) to medications like laxatives and agents that stimulate gut motility. It's important to address constipation promptly as chronic cases can lead to complications such as hemorrhoids, anal fissures, and even fecal incontinence. In severe instances, it may contribute to conditions like diverticulitis and colon cancer. 👉We have developed and extensively characterized a 𝐬𝐮𝐛𝐚𝐜𝐮𝐭𝐞 𝐜𝐨𝐧𝐬𝐭𝐢𝐩𝐚𝐭𝐢𝐨𝐧 𝐦𝐨𝐝𝐞𝐥 in rat induced by repetitive administration of loperamide (an anti-diarrhea compound) for chronic efficacy and MoA studies of compounds aiming Constipation. The model rapidly develops a decrease in total transit time associated with a strong decrease in fecal pellet output. We provide gold-standard methods to provide you with 𝐡𝐢𝐠𝐡-𝐚𝐝𝐝𝐞𝐝 𝐯𝐚𝐥𝐮𝐞 𝐝𝐚𝐭𝐚 about your health products efficacy and MoA on key in-life parameters related to constipation such as food and water intakes, fecal pellet output, circulating plasma biomarkers. In addition, we offer complementary techniques that allow performing histological and genomic analyses on key tissues and organs. 📌At Biomeostasis, we are dedicated to advancing understanding and treatment options for constipation through rigorous research and innovation. Together, let's strive towards better gastrointestinal health for all.

🌍 Understanding Liver Diseases: Key Insights on #MASLD and #MASH 🌍 Liver diseases like MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) and its severe form, MASH (Metabolic dysfunction-Associated SteatoHepatitis), are two terms used to describe liver diseases associated with metabolic dysfunctions. 👉 MASLD is characterized by the presence of fatty #liver disease in individuals with metabolic risk factors, such as obesity, insulin resistance, and dyslipidemia. On the other hand, MASH represents a more severe condition involving inflammation, fibrosis and liver cell damage in addition to fatty liver disease. The risk factors associated with these conditions include obesity, insulin resistance, type 2 diabetes, high blood pressure, and high triglycerides. Importantly, MASLD is often asymptomatic, with symptoms that may include fatigue, abdominal discomfort, and elevated liver enzymes. By 2025, MASLD is projected to surpass viral hepatitis as the leading cause of liver diseases globally, highlighting the urgent need for awareness and proactive measures. At Biomeostasis, we are leveraging our expertise in #preclinical models to drive meaningful advancements in #metabolic research. We have a long track record in running preclinical studies on MASLD and MASH in a variety of established and validated rodent models for chronic efficacy and MoA studies. • DIO MASLD model (17 weeks on 60% HFD) • Diet-induced MASH model (30 weeks on a modified AMLN diet) • STZ-DIO MASH model Stay tuned as we continue to push the boundaries of scientific exploration in MASLD and MASH research. Together with our dedicated team, we are committed to shaping a healthier future 🌿

🎉 𝗘𝘂𝗿𝗼𝘀𝘁𝗮𝗿𝘀 𝗠-𝗣𝗟𝗨𝗦 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗨𝗽𝗱𝗮𝘁𝗲 🎉 We are thrilled to share exciting progress in the #Eurostars M-PLUS project, where Biomeostasis, alongside esteemed partners Vandria SA, Greater Paris University Hospitals - AP-HP, and Bi/ond, is pushing the frontiers of muscle mitophagy drug development. The last week of June marked a significant milestone as the M-PLUS consortium convened for its first in-person meeting in Paris. This gathering provided a valuable platform for all members to exchange insights and updates on our collective efforts. The central theme of the meeting was expanding the reach of our technology by creating new disease models of Sarcopenia and DMD, and evaluating diverse compounds on these models. This initiative unlocks new application opportunities and strengthens our dedication to pioneering advancements in biomedical research. Both our CEO Bruno BARIOHAY, Ph.D and our CSO Julien ROUX, Ph.D. were attending, reflecting the importance we place on this collaborative effort and our commitment to driving its success. Together, we are making strides toward a healthier future. Stay tuned for more updates as we continue to drive forward with this groundbreaking project! #EurostarsMPLUS #MedicalInnovation #Consortium #CRO

At Biomeostasis, we are dedicated to unraveling the complexities of #sarcopenia through comprehensive research and innovative solutions. Individuals aged 80 or above face a staggering 50% risk of experiencing sarcopenia. 🔬 𝐎𝐮𝐫 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐌𝐨𝐝𝐞𝐥𝐬 𝐚𝐧𝐝 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬: Utilizing cutting-edge preclinical models and gold-standard methods, we are conducting in-depth investigations into sarcopenia. Our approach includes: - Accurate body weight and food intake measurements. - Body composition analysis using TD-NMR (Minispec LF90II Bruker. - Endurance and performance tests on treadmills, assessing parameters like running distance, VO2 max, and time-to-exhaustion. - Evaluation of muscle strength using either Grip strength devices or Aurora Platform. - Comprehensive analysis of muscular histology, proteomic, and genomic profiles to uncover underlying mechanisms. 💡 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Through our commitment to research excellence and collaboration with leading experts, we are pushing the boundaries of sarcopenia understanding and treatment. By leveraging state-of-the-art technology and novel approaches, we aim to develop targeted interventions to mitigate the impact of sarcopenia and enhance quality of life for affected individuals. 📨 Contact Julien ROUX, Ph.D. for more details! #InnovationInAging #HealthyAging #CRO

At Biomeostasis, we are dedicated to advancing the understanding and treatment of Inflammatory Bowel Diseases (#IBD). With over 10 million people affected globally, IBD remain a significant challenge in #gastroenterology. 🌟 𝐊𝐞𝐲 𝐅𝐚𝐜𝐭𝐬 𝐀𝐛𝐨𝐮𝐭 𝐈𝐁𝐃: Inflammatory Bowel Diseases (IBD) affects an estimated 1.6 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐀𝐦𝐞𝐫𝐢𝐜𝐚𝐧𝐬, with around 70,000 new diagnoses each year. While it is less common in children, IBD impact up to 80,000 youngsters in the US alone. This condition is more prevalent in developed nations, but its reach is 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐢𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬, likely due to environmental factors and lifestyle changes. Typically, IBD first strike people between the ages of 15 and 35, coinciding with crucial life stages like education, career building, and starting a family. Although there is currently 𝐧𝐨 𝐜𝐮𝐫𝐞 𝐟𝐨𝐫 𝐈𝐁𝐃, significant advancements in treatment options - including medications, dietary modifications, and sometimes surgery - can effectively manage symptoms and allow people with IBD to lead active and fulfilling lives. 🔬 𝐎𝐮𝐫 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭: 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐒𝐭𝐮𝐝𝐢𝐞𝐬: Developing advanced murine models and preclinical solutions to target the underlying causes of IBD. 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫-𝐂𝐞𝐧𝐭𝐫𝐢𝐜 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡: Ensuring flexibility, rapid response times, ethical practices, and caring for the specific needs of our clients. 𝐒𝐭𝐚𝐭𝐞-𝐨𝐟-𝐭𝐡𝐞-𝐀𝐫𝐭 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: Utilizing cutting-edge technology and in vivo pharmacology to enhance the accuracy and efficiency of our studies.   📢 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐢𝐧 𝐌𝐚𝐤𝐢𝐧𝐠 𝐚 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞: We invite healthcare professionals, researchers, and industry partners to collaborate with us in our mission to improve the lives of those affected by IBD. Together, we can drive innovation and bring hope to millions. #CRO

🚀 Explore the Future of the CRO Market with Us! 🚀   At Biomeostasis, we're thrilled to unveil insights into the future of the Contract Research Organizations (CROs) market, as depicted in the latest GMI 2032 market analysis. With the market currently valued at $56.5 billion USD and projected to skyrocket to $108 billion USD by 2032, there's ample excitement ahead. What's propelling this growth? It's a blend of increased R&D investments, a surge in clinical trials—particularly in burgeoning markets-, an uptick in R&D outsourcing, and notable technological strides. Yet, amidst this optimism, we recognize challenges. Intellectual property and regulatory complexities stand as major concerns. The COVID-19 pandemic, though moderately affecting the CRO landscape, has spurred clinical trials for vaccines and treatments, showcasing the industry's resilience. Regionally, while North America boasts a robust $24.4 billion USD market in 2022, promising growth trajectories emerge across Europe, Asia-Pacific, Latin America, and the Middle East & Africa. As a French CRO, we're committed to driving innovation. While industry giants lead the charge, smaller players like us play a pivotal role in fostering agility and personalized solutions. Our recent collaborations, like our partnerships with Vandria SA, Bi/ond and AP-HP, Assistance Publique - Hôpitaux de Paris exemplify our dedication to advancing research. In essence, the CRO market brims with potential, fueled by burgeoning R&D investments, expanding clinical endeavors, and tech integration. As CEO of Biomeostasis, I invite you to embark on this transformative journey with us. Let's harness these opportunities and redefine excellence together! #MarketAnalysis #investment #CRO

🥼 𝐌𝐞𝐞𝐭 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦!  Today, we introduce you to Dr. Julie Marcotorchino, a Senior Project Leader at Biomeostasis! 🚀 Julie has been with us for 10 years, following her PhD at the Aix-Marseille Université. Julie is a passionate and dedicated expert who thrives on learning and tackling new challenges. Her contributions are essential to advancing our understanding of #nutrition and its significant impact on health. As a Senior Project Leader, she loves exploring new #innovations and consistently enhancing her skillset. Swipe to discover her #skills! 👇 #Career #CRO #WomenInSTEM

🚀 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗮𝗻𝗱 𝗔𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗢𝗯𝗲𝘀𝗶𝘁𝘆 #Obesity is a chronic and complex #health condition defined as excess accumulation of fat, often leading to medical complications. It stems from a combination of factors, includine genetic predisposition, poor dietary habits, and sedentary lifestyle. The prevalance of obesity has surged globally, becoming a significant #PublicHealth concern. 890 million adults are living with obesity, and 5 million people died prematurely in results of obesity (2019, WHO). Not only does obesity increase the risk of various chronic diseases, such as type 2 diabetes, cardiovascular diseases, respiratory diseases, kidney diseases, musculoskeletal complications, and certain cancers, but it also impacts individuals’ quality of life, mental health, and socioeconomic status. Obesity presents a substantial challenge for healthcare providers and pharmaceutical companies alike, driving the demand for innovative solutions and treatments.

💪𝐀𝐫𝐞 𝐲𝐨𝐮 𝐨𝐫 𝐲𝐨𝐮𝐫 𝐭𝐞𝐚𝐦 𝐟𝐚𝐜𝐢𝐧𝐠 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐨𝐧 #muscle 𝐰𝐚𝐬𝐭𝐢𝐧𝐠 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬?  Muscle wasting, characterized by a loss of muscle mass and strength, can stem from various medical conditions. Symptoms range from reduced muscle strength to decreased physical performance. At Biomeostasis, we are equipped with robust expertise in these area, as well as in #preclinical compound evaluation. We specialize in : - #Sarcopenia - #Cachexia - Duchenne muscular dystrophy (#DMD), Let's work together to make strides in combating these conditions! 🏃 Contact Julien ROUX, Ph.D. to find out more about our solutions 📨 #CRO #Health